The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula:

##STR00001##

wherein, R.sup.1 is a 5- to 6-membered ring group which may be substituted; X.sup.1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X.sup.2 is a bivalent group of 1 to 4 atoms; Z.sup.1 is a bivalent cyclic ring group or the like; Z.sup.2 is a bond or the like; and R.sup.2 is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.

The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula:

##STR00001##

wherein, R.sup.1 is a 5- to 6-membered ring group which may be substituted; X.sup.1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X.sup.2 is a bivalent group of 1 to 4 atoms; Z.sup.1 is a bivalent cyclic ring group or the like; Z.sup.2 is a bond or the like; and R.sup.2 is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.

The disclosure includes high purity compounds having CCR5 and/or CCR2 antagonism, or a salt thereof, and processes for synthesizing the same.

The disclosure includes high purity compounds having CCR5 and/or CCR2 antagonism, or a salt thereof, and processes for synthesizing the same.

The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula: ##STR00001##
wherein, R.sup.1 is a 5- to 6-membered ring group which may be substituted; X.sup.1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X.sup.2 is a bivalent group of 1 to 4 atom; Z.sup.1 is a bivalent cyclic ring group or the like; Z.sup.2 is a bond or the like; and R.sup.2 is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.

The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula: ##STR00001##
wherein, R.sup.1 is a 5- to 6-membered ring group which may be substituted; X.sup.1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X.sup.2 is a bivalent group of 1 to 4 atom; Z.sup.1 is a bivalent cyclic ring group or the like; Z.sup.2 is a bond or the like; and R.sup.2 is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.

The present invention provides compounds of Formula (I):

P-Ma (I)

or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

The present invention provides compounds of Formula (I):

P-Ma (I)

or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Described are mitochondria-targeted anti-tumor agents, and methods of making and using the same for the treatment of disorders associated with unwanted cell proliferation.

Described are mitochondria-targeted anti-tumor agents, and methods of making and using the same for the treatment of disorders associated with unwanted cell proliferation.